Valeur2022202320242025Total du passif3.92 B3.56 B3.44 B3.85 BTotal des capitaux propres-67.6 M-30 M-36.2 M-15.4 MTotal du passif et des capitaux propres8.86 B8.56 B6.42 B5.77 BDette totale208.7 M140.2 M——Dette nette-136.3 M-27.1 M——
QuidelOrtho Corporation - Common Stock
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.